Who is building Cuneate, where it stands, and what happens next.
Founding team
Three medical students and an engineer.
Built by people who met this problem on the ward, not in a market report.
HS
Hrushi SaranuMedical StudentVascular Surgery
ZM
Zubin MathewMedical StudentNeurology
SK
Samuel KimMedical StudentNeurosurgery
GM
Genova MongaloComputer ScienceEngineering
We kept meeting the same patient. Discharged, doing fine on paper, and nobody would know
otherwise for six weeks. Cuneate is the thing we wanted to hand them on the way out the
door.
Where we are
Built and tested. Trials are the next step.
The platform is built and in testing, with clinical validation in
preparation at two identified sites. What follows is the evidence base.
First 9 months
Identified the founding team
Organized the LLC
Developed the prototype
Partnered with key physician stakeholders
Past 3 months
Identified 2 clinical trial sites
Validated market need
Secured initial funding
Determined the highest-value biomarkers
Now
Implementing digital biomarkers
Finalizing the MVP for TestFlight
Organizing clinical trial infrastructure
Next 6 months
Publishing clinical trial data
First sales, with research continuing
Collaborating with larger health systems
Beyond
Concierge and telehealth clinics
Scaling to other neurological disease
Advancing the underlying technology
Go to market
Clinical partnerships first, scale second.
The route to becoming the standard runs through published evidence and
nothing else.
CurrentPhase 1
Clinical validity
One to two pilot sites
Validation against clinical measures
Adjustments and safety review
Phase 2
Publication and expansion
Publish the trial data
Grow partner hospital systems
Move from pilot to program
Phase 3
Become the standard
Enter regular clinical practice
Scale into other pathology
Same platform, new conditions
Talk to us.
Questions, feedback, or interest in a pilot — we’d like to hear from you.
